Welcome to our dedicated page for Transcode Therapeutics news (Ticker: RNAZ), a resource for investors and traders seeking the latest updates and insights on Transcode Therapeutics stock.
TransCode Therapeutics Inc (RNAZ) is a clinical-stage biopharmaceutical company pioneering RNA-based therapies for metastatic cancers through its proprietary TTX nanoparticle delivery platform. This news hub provides investors and researchers with essential updates on the company’s progress in developing targeted treatments, including its lead candidate TTX-MC138 designed to inhibit metastasis-driving microRNA-10b.
Our curated collection offers immediate access to official press releases, clinical trial milestones, and strategic partnership announcements. Users will find updates spanning multiple critical areas: TTX platform advancements, regulatory submissions, financial disclosures, and peer-reviewed research collaborations in oncology.
Key content includes developments around the company’s nanoparticle delivery system, trial results for metastatic cancer therapies, and analyses of RNAZ’s position within the competitive oncology therapeutics market. All materials are sourced directly from company filings and verified industry publications to ensure reliability.
Bookmark this page for streamlined tracking of TransCode’s innovations in RNA oncology. Check regularly for new insights into how the company’s cutting-edge approach to metastatic disease treatment continues to evolve through clinical validation and strategic execution.
TransCode Therapeutics (RNAZ) announced the appointment of Frank J. Slack, PhD, a leader in small noncoding RNA research, to its advisory board. His expertise is anticipated to bolster the company’s mission as it enters clinical development phases with its lead product, TTX-MC138, aimed at treating metastatic cancers responsible for approximately 90% of cancer deaths globally. Slack's background includes pioneering studies on microRNAs, which are crucial for cancer targeting. This strategic addition aligns with upcoming first-in-human studies intended to advance TransCode's innovative RNA therapeutic approaches.
TransCode Therapeutics (NASDAQ: RNAZ) reported its Q2 2022 financial results and business advancements. The company is progressing with its therapeutic programs, aiming to submit an exploratory Investigational New Drug application for TTX-MC138. Notably, it received orphan drug designation for TTX-siPDL1 targeting pancreatic cancer. Cash reserves stood at $13.4 million as of June 30, 2022, down from $20.8 million at the end of 2021, with an operating loss of $4.7 million. A strategic alliance with MD Anderson Cancer Center was also announced to enhance RNA-targeted therapies.
TransCode Therapeutics (Nasdaq: RNAZ) announced a strategic alliance with MD Anderson Cancer Center to enhance its RNA-targeted oncology pipeline. The collaboration focuses on validating therapeutic candidates through preclinical studies, which will aid future clinical trials, including the lead candidate TTX-MC138 aimed at treating metastatic cancers. The partnership aims to leverage MD Anderson's expertise to develop innovative cancer treatment options. TransCode emphasizes its commitment to advancing RNA-based therapies for improved patient outcomes.
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics (NASDAQ: RNAZ) announced the filing of a provisional patent application (US 63/356,449) for a method combining radiotherapy with RNA-based nanoparticles for cancer therapy. The approach aims to activate the immune system by leveraging tumor-derived neoantigens and activating the RIG-I signaling pathway. CEO Michael Dudley emphasized the potential for enhanced cancer treatment through this technology. TransCode is advancing its lead candidate, TTX-MC138, into clinical studies, underscoring its commitment to innovative cancer solutions.
BOSTON, June 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics (Nasdaq: RNAZ) announced its attendance and presentation at the BIO International Convention from June 13-16, 2022, in San Diego, CA. CEO Michael Dudley will discuss the company’s RNA-based scientific discoveries that could significantly enhance cancer treatment. He will also outline plans for the lead candidate, TTX-MC138, aimed at treating metastatic disease and progressing to its First-in-Human clinical trial.
TransCode Therapeutics (Nasdaq: RNAZ) has secured a $2.3 million funding from a Fast-Track SBIR grant to continue clinical development of TTX-MC138, its lead candidate for treating advanced solid tumors.
The second tranche of this funding was activated following the achievement of a program milestone in Q1 2022, which contributed $1.1 million to the company. The CEO has confirmed plans to submit an eIND for a first-in-human study this year, aiming to validate the novel delivery platform targeting microRNA-10b, implicated in metastatic disease.
TransCode Therapeutics (Nasdaq: RNAZ) will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, with a live presentation scheduled for May 24 at 7:00 a.m. ET. CEO Michael Dudley will highlight the Company’s RNA-based innovations aimed at advancing cancer treatment, including the upcoming First-in-Human trial for its lead candidate, TTX-MC138, planned for late 2022. This candidate targets metastatic disease, responsible for about 90% of cancer deaths globally. The presentation will be available via live feed and on-demand.
TransCode Therapeutics (NASDAQ: RNAZ) has signed an option agreement to negotiate an exclusive license for a radiotheranostic technology aimed at enhancing cancer treatment. Developed by Dr. Zdravka Medarova and her team at Massachusetts General Hospital, this technology involves radiolabeled nanoparticles that could improve diagnostics and therapeutic capabilities. CEO Michael Dudley expressed optimism about integrating this technology with their existing RNA delivery system, TTX. TransCode plans to submit an exploratory IND application to initiate a Phase 0 First-in-Human trial for TTX-MC138 in late 2022.
TransCode Therapeutics (NASDAQ: RNAZ) reported its Q1 2022 financial results, highlighting a cash position of $16.9 million. The company plans to submit an exploratory IND application for its lead candidate, TTX-MC138, in a Phase 0 study targeting advanced solid tumors. Financially, expenses rose significantly, with R&D costing $1.9 million and a total operating loss of $3.5 million. TransCode achieved a milestone in its SBIR grant and aims for further funding to support ongoing projects and team expansions, while also filing for new patents in RNA oncology.
TransCode Therapeutics (NASDAQ: RNAZ) announced that Dr. Zdravka Medarova will moderate the 7th Annual RNA Medicine Symposium on April 28, 2022. The event, co-sponsored by Harvard Medical School and Beth Israel Deaconess Medical Center, will feature esteemed speakers from various prestigious institutions. Dr. Medarova will also present at the 3rd Annual RNAi-Based Therapeutics Summit, discussing novel siRNA-based therapies for cancer, including their applications and the potential of RNAi in tumor targeting. TransCode aims to advance RNA oncology therapeutics to improve patient outcomes.
FAQ
What is the current stock price of Transcode Therapeutics (RNAZ)?
What is the market cap of Transcode Therapeutics (RNAZ)?
